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Abstract
Melanocyte-specific CD8
+ cytotoxic T lymphocytes (CTLs) play a pivotal role in vitiligo-induced depigmentation. Yet, the
mechanisms underlying the high frequency of generalized autoimmune disorders associated with generalized vitiligo (GV)
are unknown. We hypothesized that an imbalance between activated CD8
+ CTLs and regulatory T cells (Tregs) exists in
patients with GV . Assessment of the circulating CD8
+ CTLs and Tregs by flow cytometric analysis revealed an obvious
expansion of CD8
+ CTLs and a concomitant decrease in Treg cells in GV patients. The percentages of skin infiltrating CD8
+
CTLs and Tregs were evaluated by immunohistochemistry and revealed dramatically increased numbers of both CD8
+ CTLs
and Tregs in the perilesional skin of GV patients. However, peripheral Tregs were impaired in their ability to suppress the
proliferation and cytolytic capacity of autologous CD8
+ T cells, suggesting that a functional failure of Tregs and the hyper-
activation of CD8
+ CTLs may contribute to progressive GV. Our data indicate that reduced numbers and impaired function
of natural Tregs fail to control the widespread activation of CD8
+ CTLs, which leads to the destruction of melanocytes and
contributes to the elevated frequency of various associated autoimmune diseases. This knowledge furthers our
understanding of the mechanisms of immune tolerance that are impaired in GV patients and may aid in the future
development of effective immunotherapy for GV patients.
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Introduction
Vitiligo is an acquired depigmentation disorder characterized
by the loss of melanocytes from the epidermis. This condition
affects approximately 0.5–1% of the world’s population [1]. The
exact etiology of vitiligo remains obscure, but autoimmune factors
have been strongly implicated in the development of the disease,
especially in generalized vitiligo (GV), because approximately 30%
of vitiligo patients are affected with at least one additional
autoimmune disorder [2].
CD8
+ T cell-mediated tissue damage has been demonstrated in
common organ-specific autoimmune diseases, such as type I
diabetes and multiple sclerosis, and a role for CD8
+ T cells has
been postulated in the pathogenesis of GV . Previous studies have
largely focused on melanocyte-specific cytotoxic T lymphocytes
(CTLs) and identified their pivotal role in inducing melanocyte
destruction [3–5]. The presence or activation of melanocyte-
specific CTLs, however, does not explain why GV patients often
present with other generalized autoimmune conditions, such as
autoimmune thyroid disease, Addison’s disease, systemic lupus
erythematosus and pernicious anemia [2]. Several reports have
shown that increases in globally activated CD8
+ CTLs correlate
with disease activity in various autoimmune disorders [6,7]. We
therefore hypothesized that the skin depigmentation of GV
patients resulted from a global expansion of activated CD8
+
CTLs that progressively destroyed melanocytes and led to a high
frequency of associated generalized autoimmune diseases. Thus
far, the immune mechanisms underlying the induction and
activation of autoreactive CD8
+ CTLs and the loss of tolerance
to auto-antigens are not clear.
CD4
+ CD25
+ CD127
2 Foxp3
+ regulatory T cells (Tregs) are
important in maintaining self-tolerance and regulating immune
responses in both physiological and disease conditions [8].
Accumulating data indicate that a deficiency or dysfunction of
Tregs is associated with impaired immune homeostasis and the
development of autoimmune diseases. To date, few papers have
investigated Treg numbers or function in GV patients. One report
revealed a defect in Treg cell homing to the skin, based on the
finding of drastically reduced Treg numbers in vitiligo skin without
any systemic drop in their abundance or activity [9]. In contrast, a
recent report identified increased numbers of Tregs in perilesional
skin despite a functional defect of circulating Tregs in progressive
vitiligo [10]. Whether the prevalence and/or function of Tregs are
truly impaired in GV patients is still controversial. Moreover,
studies presenting the reciprocal relationship between CD4
+
CD25
+ CD127
2 Foxp3
+ Tregs and CD8
+ CTLs in GV
progression are lacking.
To address these issues, 50 GV patients were enrolled in this
study. The frequencies of Tregs and CD8
+ CTLs were analyzed in
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37513serum or skin samples of GV patients with progressive or stable
disease, respectively. The ability of Tregs to suppress polyclonal
CD8
+ T cell responses was also assessed using cells from GV
patients. Our results showed that CD8
+ CTLs that express
interferon-c (IFN-c), Granzyme B (GrB) and Perforin exhibited a
global expansion, whereas circulating CD4
+ CD25
+ CD127
2
Treg cells were significantly reduced among the peripheral blood
mononuclear cells (PBMCs) of GV patients. Depletion of natural
Tregs was related to the expansion of CD8
+ CTLs. Moreover,
while both CD8
+ T and Foxp3
+ Tregs were increased in the
perilesional skin of GV patients, we reasoned that GV patients’
Tregs would exhibit a functional failure based on the observation
that circulating Tregs failed to effectively suppress CD8
+ T cell
proliferation and/or the release of cytolytic molecules. Our data
indicate that the pathophysiology of GV, and its associated
increase risk of autoimmune disorders, might be linked to a defect
in the homeostatic control of activated CD8
+ CTLs and/or
natural Treg cell subpopulations.
Results
Highly enriched circulating CD8
+ cytotoxic T
lymphocytes in patients with GV
Effector CD8
+ CTLs play a key role in the host defense through
the production of cytokines, such as IFN-c, and the effector
molecules, GrB and Perforin. CD8
+ CTLs can also support
deleterious effects when they react against self tissues. As the actual
functional molecules for killing target cells, IFN-c, GrB and
Perforin can be used as markers for effector CD8
+ CTLs [11]. In
our study, PBMCs obtained from 38 progressive GV patients, 12
stable GV patients, and 20 normal controls were analyzed for the
frequency of CD3
+ CD8
+ T cells and the expression of IFN-c,
GrB and Perforin by flow cytometry (Figure 1A). There was a
significantly higher number of circulating IFN-c
+ CD8
+ T among
CD3
+ T cells in progressive GV (mean 6 SD 14.8063.56%;
P,0.01) and stable GV (13.4663.69%; P,0.01) patients com-
pared to healthy individuals (8.6662.59%) (Figure 1B, left). The
percentage of GrB
+ CD8
+ T cells among circulating CD3
+ T cells
was significantly increased in active GV (40.16614.60%;
P,0.001) and inactive GV (32.47612.77%; P,0.05) patients
compared to healthy individuals (18.59611.73%) (Figure 1B,
middle). In addition, we observed that Perforin expression in the
CD3
+ CD8
+ T cell subset was significantly higher in GV patients
(progressive GV, 5.6462.08%, P,0.001; stable GV,
4.4862.03%, P,0.01) than in normal controls (2.2561.26%)
(Figure 1B, right). Interestingly, no significant difference in the
numbers of circulating IFN-c
+ CD8
+ T cells, GrB
+ CD8
+ T cells
and Perforin
+ CD8
+ T cells in CD3
+ T cells was observed between
patients with progressive GV and stable GV (Figure 1B).
We next questioned whether the percentage of CD8
+ CTLs
varied within the same individual in relation to disease status. To
assess this, 6 individuals with progressive GV were tested
longitudinally; there was a significant decrease in the percentage
of CD8
+ CTLs after the patient’s disease was stabilized by
treatment with oral traditional Chinese herbs and topical steroids
(Figure 1C).
Decrease of circulating CD4
+ CD25
+ CD127
2 Treg cells in
GV patients
Natural Treg cells play a key role in peripheral immune
tolerance and prevent the occurrence of autoimmune diseases. In
this study, natural Treg cells were quantified by flow cytometric
analysis, according to their CD4, CD25 and CD127 surface
marker expression [12] (Figure 2A). The percentage of CD4
+
CD25
+ CD127
2 T cells was significantly decreased in the 38
patients with progressive GV (7.0%61.8%, P,0.001) and the 12
patients with inactive disease (7.2%61.4%, P,0.01) compared to
the 20 healthy controls (10.4%63.2%) (Figure 2C). However, the
numbers of circulating Tregs did not differ significantly between
progressive GV and stable patients (P.0.05). We compared the
frequency of natural Treg cells among CD4
+ T cells and the
frequency of IFN-c
+ CD8
+, GrB
+ CD8
+ or Perforin
+ CD8
+ cells
among CD3
+ T cells in progressive GV patients, revealing a strong
negative correlation between these two cell populations (Spearman
correlation coefficient, r=20.512, P=0.001, n=38; r=20.524,
P=0.001, n=38; r=20.585, P,0.001, n=38) (Figure 2B).
We next sought to determine whether the percentage of natural
Treg cells varied within the same individual in relation to disease
status. Six individuals were tested twice, once during active GV
and once after their diseases were stabilized with treatment. The
percentage of natural Treg cells within these patients increased
significantly after treatment (P,0.05) (Figure 2D).
Increased frequency of CD8
+ T cells and Tregs in GV skin
tissue samples
To visualize CD8
+ T cells and Treg cells in the skin of GV, we
performed immunohistochemical staining for CD8 and Foxp3
expression. The number of cells staining positive for these markers
were identified in skin tissue samples from normal controls or in
non-lesional, perilesional and lesional skin samples from GV
patients. Foxp3 is a reliable and specific marker of Tregs because it
serves as the dedicated mediator of the genetic program governing
Treg cell development and function [13–15]. We observed that
perilesional skin samples from patients with progressive GV
exhibited pathologic changes including a large number of
infiltrating CD8
+ T and Foxp3
+ cells predominantly adjacent to
the epidermal basal layer (Figure 3A).
CD8
+ T cell counts in each high-power field (4006) were
significantly increased in 16 perilesional skin samples from patients
with progressive GV (mean 6 SD 22.9662.29), compared to skin
from 6 healthy individuals (12.7966.89, P,0.05), the 2 lesional
skin samples from patients with stable disease (10.8366.53,
P,0.05) or 8 non-lesional GV skin samples (11.1964.4,
P,0.05). However, no significant difference was observed between
lesional skin and non-lesional skin from GV patients or healthy
skin from controls (P.0.05) (Figure 3B). In contrast to previous
studies [10], we observed that Foxp3
+ lymphocyte infiltration was
also significantly increased in the 16 perilesional skin samples from
patients with progressive GV (9.3962.66) compared to any of the
other sample types: skin samples from 6 healthy individuals
(3.6963.04, P,0.01), lesional skin from patients with stable
disease (n=2; 2.4960.6, P,0.01) or non-lesional GV skin (n=8;
3.2862.47, P,0.05) (Figure 3C). No significant difference was
observed between the lesional and non-lesional skin of GV patients
or healthy skin from control individuals (P.0.05) (Figure 3C).
Importantly, we observed a positive correlation between the
number of CD8
+ T cells and Foxp3
+ cells in 16 perilesional skin
samples from progressive GV patients (Spearman correlation
coefficient, r=0.706, P,0.001) (Figure 3D). These results provide
evidence that Tregs can be recruited to inflammatory sites from
the circulation, and the increase in local CD8
+ T cells and Foxp3
+
cells might be involved in the GV disease process.
Analysis of Treg-mediated suppression of polyclonal
CD8
+ T cell responses
Treg/CD8
+ T cell cocultures were used to evaluate the in vitro
suppressive capacity of Tregs toward CD8
+ T cells using
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37513Figure 1. Circulating CD8
+ CTLs are increased significantly in GV patients. (A) IFN-c, GrB and Perforin–expressing cells were detected by
intracellular staining. Values are the percentage of IFN-c
+ CD8
+, GrB
+ CD8
+ or Perforin
+ CD8
+ cells among CD3
+ T cells (Representative cases). (B) Flow
cytometric analysis of IFN-c
+ CD8
+, GrB
+ CD8
+ and Perforin
+ CD8
+ cells within the CD3
+ T cell populations from patients with progressive GV (n=38),
CD8
+ CTL and Treg Cells in Generalized Vitiligo
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37513magnetically sorted CD8
+ T cells and CD4
+ CD25
+ Treg cells
from either progressive GV patients (n=6) or normal control
subjects (n=4). T cells were labeled with CFSE and cocultured in
the presence of anti-CD3 and anti-CD28 antibodies (anti-CD3/
CD28 Abs) at the ratio of either 1:0.1 or 1:1 (Figure 4A). By
analyzing CFSE intensity by flow cytometric analysis on day 5, we
detected a dose-dependent suppression of autologous CD8
+ T cells
by CD4
+ CD25
+ Treg cells from both normal controls and GV
patients. However, Tregs from GV patients showed a significantly
lower suppressive capacity than that of normal controls (mean 6
SD 11.9763.08% vs. 17.9264.15% at a ratio of 1:0.1, P,0.05;
27.7665.71% vs. 49.0365.80% at a ratio of 1:1, P,0.01)
(Figure 4C). In addition, the CD4
+ CD25
+ T cells of normal
controls and the majority of GV patients (5/6) were hyporespon-
sive to polyclonal TCR stimulation when cultured alone, as the
majority of Tregs remained CFSE
high (Figure 4B). These data
stable GV (n=12) and control subjects (n=20). *=P,0.05, **=P,0.01, ***=P,0.001. (C) The CD8
+ CTL population of 6 patients was monitored
longitudinally: The percentage of IFN-c
+ CD8
+ T cells, GrB
+ CD8
+ T cells and Perforin
+ CD8
+ T cells was measured initially during GV progression and
again following stabilization after treatment. *=P,0.01, **=P,0.001.
doi:10.1371/journal.pone.0037513.g001
Figure 2. Circulating CD4
+ CD25
+ CD127
2 Tregs are decreased significantly in GV patients. (A) Human PBMCs were labeled with
lymphocyte-specific antibodies (CD4, CD25 and CD127). Representative flow data showing the gating strategy and percent of natural Treg cells
within the CD4
+ T cell population are given for one patient from each of the 3 studied groups. (B) A negative correlation was found between the
frequency of CD4
+ natural Treg cells and the expression of IFN-c (r=20.512, P=0.001), GrB (r=20.524, P=0.001) or Perforin (r=20.585, P,0.001)
from CD3
+ CTLs in patients with progressive GV (n=38). (C) The results of the flow cytometric analysis of natural Treg cells in patients with
progressive GV (n=38), stable GV (n=12) and control subjects (n=20) are shown. *=P,0.01, **=P,0.001. (D) Longitudinal monitoring of natural
Treg cells in 6 patients. The percentage of CD4
+ natural Treg cells was measured twice: once during a vitiligo flare and once following resolution after
treatment. *=P,0.05.
doi:10.1371/journal.pone.0037513.g002
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+ CD25
+ Treg cells in progressive GV patients
could not effectively suppress CD8
+ T cell proliferation.
Interestingly, when cocultured with autologous Tregs, CD8
+ T
cells of GV patients had markedly enhanced levels of IFN-c and
TNF-a upon stimulation with anti-CD3/CD28 Abs compared to
healthy individuals (Figure 4D and E). These findings suggest that
the Tregs of GV patients may not effectively suppress the
production of certain cytokines involved in CD8
+ T cell activation.
Discussion
A functional CD8
+ T cell response is an essential component of
the adaptive immune response to various cancers and pathogens
[16]. Upon engagement with antigen, naive CD8
+ T cells rapidly
expand and differentiate into effector CD8
+ T cells, which
produce cytokines, including IFN-c, and effector molecules, such
as GrB and Perforin, that mediate a local inflammatory response
and effect target cell apoptosis [17,18]. Although effector cytotoxic
T lymphocytes (CTLs) play a key role in host defense, they can be
detrimental when they react against self tissues. CD8
+ T cell-
mediated tissue damage has been demonstrated in many
autoimmune diseases, including vitiligo [19,20]. Substantial
evidence suggests that increased numbers of melanocyte antigen-
reactive CD8
+ T cells contribute to the pathogenesis of GV
[3,21,22]. However, they fail to explain why generalized
autoimmune diseases are present at elevated frequencies among
GV patients.
According to a large survey on the epidemiology of vitiligo and
associated autoimmune diseases in 2,624 Caucasian probands,
approximately 30% of vitiligo patients reported at least one
associated autoimmune diseases [2]. The most frequent vitiligo-
associated disorder was autoimmune thyroid disease, principally
Hashimoto’s thyroiditis, occurring in more than 19% of adult
Caucasian vitiligo probands. Pernicious anemia, Addison’s disease,
systemic lupus erythematosus and inflammatory bowel disease all
occurred at significantly increased frequencies in vitiligo probands.
We previously performed a preliminary survey (unpublished) on
associated autoimmune diseases and allergic diseases in 118
Chinese GV patients and observed that 35.59% of GV patients
declared at least one associated autoimmune disease or allergic
disease. The most frequent vitiligo-associated disease was thyroid-
itis, occurring in 14.41% of patients. Other autoimmune or
allergic phenomena reported in this GV cohort were as follows:
urticaria 11.02%, allergic rhinitis 11.02%, asthma 6.78%, eczema
2.54%, systemic lupus erythematosus 0.85% and psoriasis 0.85%.
These results confirm previous evidence of an association between
GV and other autoimmune diseases [23,24] and clarify the
magnitude of these associations in Caucasian and Chinese
patients.
CD8
+ T lymphocytes play a significant role in autoimmune
disorders, as demonstrated in several reports that identify that an
increase in the number of activated CD8
+ T lymphocytes
expressing Perforin and GrB correlates with disease activity in
patients with systemic lupus erythematosus [6] and multiple
sclerosis [7]. These data suggest that widespread activation of
CD8
+ CTLs might be involved in disease flare-ups. We therefore
hypothesized that global activation of CD8
+ CTLs may correlate
with GV disease activity and that this activation was responsible
for the progress of depigmentation and an increased frequency of
associated autoimmune disorders in GV patients. Thus, our
studies were designed to delineate the ability of circulating CD8
+
Figure 3. Skin-infiltrating CD8
+ cells and Foxp3
+ cells in GV patients. (A) Consecutive sections were used for immunohistochemical
detection of T cells expressing CD8 or Foxp3
+ in skin samples from healthy controls or GV patients (representative fields, 2006). Positive cells appear
brown. Both CD8
+ (B) and Foxp3
+ (C) T cell numbers were increased significantly in the perilesional (PL) tissues of progressive GV patients (n=16). In
contrast, no significant differences were observed between lesional (L) (n=2) and non-lesional GV skin (NL) (n=8), as compared to normal skin from
unaffected adults (Cont) (n=6). *=P,0.05, **=P,0.01. (D) The number of CD8
+ and Foxp3
+ T cells in perilesional GV skin samples exhibited a
positive correlation (r=0.706, P,0.001; n=16). Values in B–C are the mean and SD.
doi:10.1371/journal.pone.0037513.g003
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molecules and cytokines upon stimulation with CD3/CD28 Abs.
In our study, we detected effector CD8
+ CTLs in the circulation
of GV patients, based on their expression of IFN-c, GrB and
Perforin. These specific effector molecules are frequently used in
equine research as a surrogate marker for cytotoxic cell activity
[25] because studies have shown that their expression correlates
well with CD8
+ T cell cytotoxic activity in PBMC cultures [26].
Herein, we show that patients with progressive GV exhibit an
increased proportion of CD8
+ cells expressing IFN-c, GrB and
Perforin compared to healthy individuals (Figure 1). This
demonstrates an increased prevalence of activated CD8
+ CTLs
among PBMCs in GV patients, especially in patients with
progressive disease. Furthermore, our data show that an increased
proportion of CD8
+ T cells also accumulate in the perilesional skin
of progressive GV patients, especially in areas adjacent to
disappearing melanocytes. These data suggest that CD8
+ CTLs
could migrate to sites of inflammation and participate in the
destruction of melanocytes, thereby promoting vitiligo-associated
depigmentation (Figure 3). Taken together, these data demon-
strate that the proportion of CD8
+ CTLs in both circulating and
perilesional skin are enhanced in the setting of progressive GV,
suggesting that a global expansion of CD8
+ CTLs might be
involved in the development of GV. In addition, we observed that
the prevalence of circulating CD8
+ CTLs decreased significantly
after efficacious treatment with oral Chinese herbs and topical
steroids. Thus, the frequency of activated CTLs correlates with
disease activity, whereas a normalization of this frequency may
precede the clinical stabilization of GV and may be used as a
predictive factor of disease outcome.
In the proliferation assay, CD8
+ T lymphocytes from progres-
sive patients cultured alone showed hyper-activation and produced
more IFN-c and TNF-a upon stimulation with anti-CD3/CD28
Abs, compared with CD8
+ T cells from control individuals. These
data suggest that the cytotoxic function of CD8
+ T cells may be
hyperactive in progressive GV patients (Figure 4). We hypothe-
sized that a defect in immunoregulation resulted in the global
activation of effector CD8
+ CTLs that consequently contributed to
elevated frequencies of autoimmune diseases associated with GV.
Taken together, our data disclose a new and pivotal role of
globally activated CD8
+ CTLs in GV pathogenesis.
Natural Treg cells play a key role in maintaining peripheral
tolerance in vivo through the active suppression of self-reactive T
cell activation and expansion [9]. A deficiency or dysfunction of
Tregs has been described in several autoimmune diseases, both
systemic [27,28] and organ-specific [29]. Currently, very little is
known about the function of Treg cells in GV patients. In this
study, we show that GV patients exhibit a decreased prevalence of
circulating Tregs (Figure 2) and an increased proportion of
perilesion-infiltrating Treg cells (Figure 3). Thus, regulatory T cells
are likely recruited to inflamed skin lesions from the peripheral
blood, despite a deficiency of circulating Tregs. These data are
consistent with current findings demonstrating that circulating
Tregs could migrate to sites of inflammation to balance the
autoimmune response in progressive GV [10]. Our data, however,
conflict with the findings reported by Klarquist et al. [9], who did
Figure 4. Tregs suppress proliferation and cytokine production of autologous CD8
+ T cells. (A) Detection of Treg suppression for CD8
+ T
cells. CFSE-labeled CD8
+ T cells were stimulated in the presence of CD4
+ CD25
+ Treg cells at the indicated ratios for 5 days. Cellular division was
measured by flow cytometric analysis based on the intensity of CFSE signal. Representative CFSE profiles from a GV patient and a normal control are
shown. Values given represent the percentage of CFSE
low cells among CFSE
+ T cells. (B) Treg cells are largely unresponsive to TCR stimulation.
Unlabeled and CFSE labeled CD4
+ CD25
+ T cells were cultured with anti-CD3/CD28 Abs, under the same stimulatory conditions as above, but without
autologous CD8
+ T cells present. Values given are the percentage of CFSE
low cells among CFSE
+ Treg cells (Representative cases). (C) Dose-dependent
suppression of CD8
+ T cell proliferation by CD4
+ CD25
+ T cells. The suppressive capacity of CD4
+ CD25
+ Tregs was compared between GV patients
(n=6) and normal control subjects (n=4). *=P,0.05; **=P,0.01. The production of IFN-c (D) and TNF-a (E) was determined. CD8
+ T cells were
cultured with Tregs at various ratios in the presence of anti-CD3/CD28 Ab stimulation for 48 hours. IFN-c and TNF-a release into the supernatant was
determined by an enzyme-linked immunosorbent assay. The data were from 6 progressive GV individuals and 4 healthy controls. *=P,0.05;
**=P,0.01.
doi:10.1371/journal.pone.0037513.g004
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vitiligo patients. Rather, they reported a reduced proportion of
Tregs in skin samples from vitiligo patients, leading them to
hypothesize that circulating Tregs are not recruited to vitiligo skin
lesions. This discrepancy may be explained by the small number of
patients included in their study. Nonetheless, we observed that the
percentage of circulating Treg cells increased significantly after
treatment-induced stabilization, suggesting that these Tregs
reflected disease activity, and could therefore be a predictive
factor for the stabilization of the disease.
Interestingly, the abundance of Tregs in perilesional skin could
not prevent CD8
+ T cell-mediated cytotoxic activity toward
melanocytes in progressive GV. Previous studies in some
autoimmune disorders have demonstrated that defective regula-
tory T cell function might result in autoimmune activation [30].
This led us to evaluate the ability of circulating natural Tregs from
GV patients to control CD8
+ T cell proliferation and activation.
The suppressive effects of peripheral T regulatory cells in 6
progressive GV cases were significantly reduced, demonstrating an
impairment in their ability to inhibit the proliferation and cytokine
production of stimulated autologous CD8
+ T cells. Thus, a
functional defect in Tregs might be involved in the pathogenesis of
GV disease (Figure 4). For instance, a higher recruitment of
functionally deficient Tregs in situ would not be able to regulate
the widespread activation of self-reactive CD8
+ CTLs that mediate
the progressive loss or destruction of melanocytes in GV patients
and would also explain the elevated frequency of associated
generalized autoimmunity. Our findings are consistent with a
recent report from Ben Ahmed [10] in which the suppressive
effects of peripheral CD4
+ CD25
+ T regulatory cells on
conventional CD4
+ CD25
2 T cell proliferation were analyzed in
vitiligo patients. These data revealed a functional defect in Treg
cells from 7 of 15 cases. Taken together with our findings, these
data indicate the presence of functional defects in Treg cells in
patients with progressive GV, which would permit an active
immune response against melanocytes and other self-antigens to
proceed unhindered, despite the presence and recruitment of
circulating peripheral Tregs in sites of diseases activity.
To demonstrate the relationship between the proportion of
circulating cytotoxic CD8
+ T cells and natural Treg cells, we
plotted the percentages of peripheral blood IFN-c
+ CD8
+ T cells,
GrB
+ CD8
+ T cells and Perforin
+ CD8
+ T cells against that of
Treg cells from progressive GV patient (Figure 2C). Our data
showed that these three CD8
+ CTL populations all correlated
negatively with Tregs, suggesting a possible causal association
between CD8
+ CTLs and Tregs in the development of GV.
Although concluding whether CD8
+ CTL hyperactivity is a cause
or a consequence of the quantitative and functional defects of
Tregs requires further investigation, we hypothesize that deficien-
cies and dysfunction in the Treg population fail to maintain
peripheral tolerance and lead to a copious expansion and
activation of self-reactive CD8
+ CTLs, which destroys melanocytes
and leads to a high frequency of generalized autoimmune diseases
in GV patients.
Finally, we did not notice any significant difference in the
frequency of circulating CD8
+ CTLs and CD4
+ CD25
+ CD127
2
Treg cells between patients with progressive and stable GV
(Figures 1 and 2). Two reasons may account for this observation:
(1) The small sample size of stable GV patients we studied may not
be representative of this patient population and needs to therefore
be confirmed, and (2) the classification of disease activity among
our GV patients might be faulty. At present, disease activity is
mainly assessed by the medical history information provided by
patients themselves. However, the patients’ recollection of disease
activity might not be accurate. It is conceivable that minor
expansions of old lesions or the appearance of new but small
lesions are not always noticed by the patient, especially when these
changes occur to lesions that are less conspicuous to the patient
(e.g., axillae or back). Moreover, patients with extensive vitiligo
involving more than 30% of the total body surface area also find it
difficult to assess disease activity. Thus, it is possible that some
patients with slow progressive disease were mistakenly classified as
having stable vitiligo. Thus, further investigation should aim for
more precise disease stage-classification standards.
In conclusion, our findings indicate that the imbalance of CD8
+
CTLs and natural Tregs in frequency and function might be
involved in the progression of GV. The deficiency and dysfunction
of natural Treg cell subpopulations lead to a global expansion and
widespread activation of the CD8
+ CTL population, which results
in the destruction of melanocytes and an elevated frequency of
associated autoimmune diseases in GV patients. This knowledge
furthers our understanding of the mechanisms that contribute to
the autoimmune status of GV patients and provides a new avenue
of investigation that may lead to the development of effective
immunotherapies for patients with GV.
Methods
Patients and controls
Fifty adult patients (18 women and 32 men, mean 6 SD age
38616.7 years) with a diagnosis of GV were enrolled in the study
after giving informed consent. The patients were divided into two
groups based on whether the existing lesions were spreading and/
or new lesions had appeared within the previous 6 months: an
affirmative answer to one or both of those questions led to
inclusion of the patient in the progressive GV group, whereas
patients with no increase in lesion size or number were included
the stable GV group. Thirty-eight patients were classified with
progressive GV (14 women and 24 men, age 38616 years),
whereas 12 patients were included in the stable GV group (4
women and 8 men, age 38620 years). A medication-free period
was required for both groups, which consisted of at least 1 month
for oral drugs, and 2 weeks for topical medications or photother-
apy prior to study procedures. As a control, 20 healthy individuals
from Fudan University were enrolled in our study. The protocols
involving human subjects were approved by the institutional
review boards of Zhongshan Hospital of Fudan University.
Informed consent was obtained in writing from all subjects before
performing the studies.
For the 10 patients in the group of patients with active GV, we
administrated oral traditional Chinese herbs and topical steroids
twice a day to stop progression and improve lesions. The herbs
complex is a mixture extracts of Rx. Angelicae Sinensis, Rx.
Astragali, Fructus Tribuli and Caulis Spatholobi, which appears to
be effective in halting disease progression and inducing repigmen-
tation in GV. Three months later, 6 patients in 10 cases reported
stabilization of their disease, and blood samples from these 6
patients were obtained again for analysis.
Four-millimeter skin biopsies were obtained from 18 patients
with GV. Six healthy tissue specimens were obtained from
individuals undergoing orthopedic surgery, and four healthy blood
samples were obtained from age- and gender-matched volunteers
for cell proliferation assays. The patients provided informed
consent prior to tissue collection. The study protocol was reviewed
and approved by the Zhongshan Hospital research ethics
committee.
Available patient information that was relevant to this study is
summarized in Table 1 and Table 2 for patients included in the
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respectively.
Flow cytometry
All blood samples were processed on the day of collection.
Peripheral blood mononuclear cells (PBMCs) were purified on
Ficoll gradients (GE Healthcare, Bjo ¨rkgatan, Sweden). For the
detection of natural Treg cells, PBMCs were stained with
fluorescein isothiocyanate (FITC)-conjugated anti-CD4, phycoer-
ythrin-Cy5 (PE-Cy5)-conjugated anti-CD25, and PE-conjugated
anti-CD127 (eBiosciences, San Diego, CA), according to the
manufacturer’s protocol. After staining, cells were washed twice in
fluorescence-activated cell sorting solution (phosphate buffered
saline [PBS] with 0.5% bovine serum albumin [BSA] and 0.02%
sodium azide), fixed in PBS containing 1% paraformaldehyde, and
collected the same day on a FACSCalibur system (BD Biosciences,
San Jose, CA) followed by analysis using FlowJo software (Tree
Star, San Carlos, CA). CD25
+ CD127
2 natural Treg cells were
identified within gated CD4
+ T cells.
Intracellular cytokine staining
For the detection of IFN-c, PBMCs were incubated for 4–
5 hours in RPMI 1640 (containing 10% fetal bovine serum [FBS])
with 50 ng/ml phorbol myristate acetate (PMA) and 750 ng/ml
ionomycin in the presence of 1.7 mg/ml monensin (Enzo Biochem,
Farmingdale, New York) in a tissue culture incubator at 37uC. No
incubation was performed for the detection of GrB and Perforin
molecules. For intracellular staining of IFN-c, GrB and Perforin
molecules, PBMCs were first stained with PerCP-conjugated anti-
CD3 and FITC-conjugated anti-CD8 antibodies and then fixed
and permeabilized using FIX & PERM (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions. Permeabilized
cells were then stained with either PE-conjugated anti-IFN-c or
APC-conjugated anti-GrB and PE-conjugated anti-Perforin
(eBioscience, San Diego, CA) for 20 minutes. Stained cells were
then fixed in 1% paraformaldehyde, and 4-color flow cytometric
analyses were performed using FACSCalibur and FlowJo software.
For the detection of CD8
+ cytotoxic T cells, IFN-c
+ CD8
+, GrB
+
CD8
+ or Perforin
+ CD8
+ T cells were analyzed among cells first
included in a CD3
+ gate.
Immunohistochemistry
Tissues from 18 GV patients were processed and embedded in
paraffin using routine methods. Tissue blocks were serially
sectioned to obtain consecutive sections. Immunohistochemistry
for CD8
+ and Foxp3
+ T cells was performed using the Novolink
Polymer Detection System (Novocastra, Newcastle-upon-Tyne,
UK) according to the manufacturer’s instructions. Briefly,
paraffin-embedded sections were first deparaffinized and then
hydrated. After microwave antigen retrieval, endogenous perox-
idase activity was blocked by the incubation of slides in 0.3%
H2O2, whereas nonspecific binding sites were blocked with Protein
Block (Novocastra). Primary monoclonal antibodies directed
against CD8 (Dako, Copenhagen, Denmark) and Foxp3 (Abcam,
Cambridge, UK) were used for CD8 and Foxp3 staining,
respectively. Following serial incubations with primary antibodies,
Primary Block, and secondary antibody treatment (Novolink
polymer; Novocastra), the sections were developed in a diamino-
benzidine solution and counterstained with hematoxylin. Sections
incubated with PBS only served as negative controls.
For quantification of CD8
+ and Foxp3
+ cells, skin sections were
examined microscopically at high power (4006). Five high-power
fields of each sample were selected for digital photographs. These
same five areas were counted manually by two independent
observers for the number of CD8
+ or Foxp3
+ cells in each field.
Cell isolation
All blood samples were processed on the day of collection.
PBMCs were purified by Ficoll-Hypaque density gradient
centrifugation from heparinized blood. CD4
+ CD25
+ Tregs were
isolated from PBMCs by CD4-negative selection followed by
CD25-positive selection, using the CD4
+ CD25
+ T-cell isolation
kit (Miltenyi Biotech, Teterow, Germany), with MidiMACS and
MiniMACS separator units (both from Miltenyi Biotech), accord-
ing to the manufacturer’s instructions. A CD8
+ T-cell isolation kit
(Miltenyi Biotech, Teterow, Germany) was used to isolate CD8
+
cells by CD8-negative selection. The purities of CD4
+ CD25
+
Tregs and CD8
+ T cells were 90% or greater and 98%,
respectively.
CD8
+ T cell proliferation assay and cytokine detection
Carboxyfluorescein diacetate succinimidyl ester (CFSE) (Invi-
trogen Corporation, Carlsbad, CA) was used to detect the
proliferation of CD8
+ T cells according to manufacturer’s
instruction. Briefly, freshly prepared CFSE stock solution was
added to CD8
+ or CD4
+CD25
+ T cell suspensions at a final
concentration of 4 mM and then incubated for 10 minutes at
37uC. Cells were washed and resuspended in 5 volumes of ice-cold
RPMI 1640 culture medium for 5 minutes on ice to stabilize the
CFSE staining. After two washes, CFSE-labeled cells were
resuspended and cultured with CD4
+ CD25
+ Tregs at various
ratios. In a U-bottom 96-well plate coated with 5 mg/ml anti-CD3
Abs (OKT3) (eBioscience, San Diego, CA), CFSE-labeled cells
were added at 5610
4 cells per well in RPMI 1640 (containing 10%
FBS) with 2 mg/ml soluble anti-CD28 Abs (CD28.2) and
Table 2. Patient PBMC samples involved in proliferation assay.
Patient gender Patient age (yr)
Disease duration
(yr) Disease activity Lesional Area
1
st degree relatives
with vitiligo Associated disease*
Female 49 0.5 Progressive ,1% No No
Female 45 20 Progressive 8% Yes HT
Male 27 16 Progressive 1% Yes No
Male 16 1 Progressive ,1% No No
Male 48 10 Progressive 10% No HT
Male 18 5 Progressive 8% Yes AR, Asthma
*HT=Hashimoto’s thyroiditis. AR=allergic rhinitis.
doi:10.1371/journal.pone.0037513.t002
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medium was replaced with fresh RPMI 1640 (containing 10%
FBS) with 2 mg/ml soluble anti-CD3 and anti-CD28 Abs. Cells
were harvested on day 5, and the intensity of CFSE staining of
CD8
+ T cells or CD4
+ CD25
+ Treg populations was determined
using a FACSCalibur system (BD Biosciences, San Jose, CA) and
FlowJo software (Tree Star, San Carlos, CA). The suppressive
capacity of Tregs toward CD8
+ T cells in coculture (CD8
+ T cell
to Treg ratio of 1:0.1 or 1:1) was defined as relative inhibition
based on the percentage of CFSE
low cells used as a measure of
proliferation: [1006(1-% CFSE
low CD8
+ T cells in coculture/%
CFSE
low CD8
+ T cells alone)].
For IFN-c and tumor necrosis factor-a (TNF-a) detection, the
plate was cultured for 48 hours. Cytokine release into the
supernatant was measured using the corresponding enzyme-linked
immunosorbent assay kits (Bender, Vienna, Austria), according to
the manufacturer’s instructions.
Statistical analysis
Data analysis was performed with SPSS version 12.0 for
Windows software (SPSS Inc., Chicago, IL). Quantitative data
were expressed as the mean 6 SD. Statistical significance was
determined by an analysis of variance followed by the Bonferroni
post hoc test for comparisons of multiple means or Student’s t-test.
Comparisons of the rates of circulating natural Treg cells, IFN-c
+
CD8
+, GrB
+ CD8
+ and Perforin
+ CD8
+ cells during the evolution
of disease were made by paired t-tests. Correlations were
determined by Spearman’s ranking. A P value of less than .05
was considered significant.
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